Downloads

Cr(VI) MOA Research Study data are freely available to registered users. The data are provided in the table below. Selecting “List all” will provide a complete list of all the data available. For each data download, there is a description of where the data were used, sorted by publication. Additionally, users may select “Original Data” to view unprocessed/ unaltered datasets from laboratories, etc., or “Manuscript Data” to view spreadsheets and related documents specific to analyses used for manuscripts. Users may also select a specific manuscript to view only the data associated with such (note: a list of the manuscripts is provided below the table).  All data are subject to the Cr(VI) MOA Study Privacy Policy, and users of the data have agreed to the Terms and Conditions.

 

Data Category Title Description Download
Manuscript Data
Original Data

Risk Assessment
EPA IRIS External Review Draft: Hexavalent Chromium Table 2 from Thompson et al. (2013), A chronic oral reference dose for hexavalent chromium-induced intestinal cancer Download
Manuscript Data
Original Data

MOA Hypothesis 2011
MOA Small Intestine 2013
Risk Assessment
Rodent PBPK
NTP 2-year Study Used in:
  • Figures 4, 6, and Tables 1, 2 from Thompson et al. (2011), Application of the U.S. EPA Mode of Action Framework for Purposes of Guiding Future Research: A Case Study Involving the Oral Carcinogenicity of Hexavalent Chromium;
  • Figures 1, 4, 5, 6, 10 from Kirman et al. (2012), Physiologically based pharmacokinetic model for rats and mice orally exposed to chromium;
  • Figure 10 and Table 3 from Thompson et al. (2013), Assessment of the mode of action underlying development of rodent small intestinal tumors following oral exposure to hexavalent chromium and relevance to humans;
  • Figure 1 and Table 3 from Thompson et al. (2013), A chronic oral reference dose for hexavalent chromium-induced intestinal cancer.
 
Download

 

Cr6Study Publications:

  • Ex Vivo Gastric Reduction – Proctor et al. (2012), Hexavalent chromium reduction kinetics in rodent stomach contents.
  • Cytotox/Genotox High Content Analysis – Thompson et al. (2012), Assessment of Cr(VI)-induced cytotoxicity and genotoxicity using high content analysis.
  • Human PBPK – Kirman et al. (2013), Physiologically based pharmacokinetic model for humans orally exposed to chromium.
  • MOA Hypothesis 2011 – Thompson et al. (2011), Application of the U.S. EPA Mode of Action Framework for Purposes of Guiding Future Research: A Case Study Involving the Oral Carcinogenicity of Hexavalent Chromium.
  • MOA 2013 – Thompson et al. (2013), Assessment of the mode of action underlying development of rodent small intestinal tumors following oral exposure to hexavalent chromium and relevance to humans.
  • Mouse Genomics – Kopec et al. (2012), Genome-wide gene expression effects in B6C3F1 mouse intestinal epithelia following 7 and 90 days of exposure to hexavalent chromium in drinking water.
  • Mutation (K-Ras and Micronucleus) – O’Brien et al. (2013), Assessment of K-Ras mutant frequency and micronucleus incidence in the mouse duodenum following 90-days of exposure to Cr(VI) in drinking water.
  • Genotox Potential Cr(VI) – Thompson et al. (2012), Assessment of genotoxic potential of Cr(VI) in the mouse duodenum: An in silico comparison with mutagenic and nonmutagenic carcinogens across tissues.
  • Risk Assessment – Thompson et al. (2013), A chronic oral reference dose for hexavalent chromium-induced intestinal cancer.
  • Rat 90 Day – Thompson et al. (2012), Comparison of the Effects of Hexavalent Chromium in the Alimentary Canal of F344 Rats and B6C3F1 Mice Following Exposure in Drinking Water: Implications for Carcinogenic Modes of Action.
  • Rat and Mouse Genomics – Kopec et al. (2012), Comparative toxicogenomic analysis of oral Cr(VI) exposure effects in rat and mouse small intestinal epithelia.
  • Rodent PBPK – Kirman et al. (2012), Physiologically based pharmacokinetic model for rats and mice orally exposed to chromium.